journal
MENU ▼
Read by QxMD icon Read
search

Translational Lung Cancer Research

journal
https://www.readbyqxmd.com/read/28151537/rebuttal-from-dr-bezjak-and-dr-giuliani
#1
EDITORIAL
Meredith Giuliani, Andrea Bezjak
No abstract text is available yet for this article.
December 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28151535/pros-after-stereotactic-ablative-radiotherapy-for-a-peripheral-early-stage-non-small-cell-lung-cancer-radiological-suspicion-of-a-local-recurrence-can-be-sufficient-indication-to-proceed-to-salvage-therapy
#2
EDITORIAL
https://www.readbyqxmd.com/read/28149768/metastatic-lung-cancer-in-the-age-of-targeted-therapy-improving-long-term-survival
#3
COMMENT
Jaydira Del Rivero, Lindsey Enewold, Anish Thomas
Epidermal growth factor receptor (EGFR) mutations are the most frequent targetable genetic abnormality observed in non-small cell lung cancer (NSCLC). More than a decade after EGFR mutations were shown to predict sensitivity to EGFR-tyrosine kinase inhibitors (EGFR-TKI), retrospective cohort studies are now identifying and characterizing 5-year survivors. While these studies indicate subsets of patients achieving long-term survival, there is paucity of data pertaining to the long-term survival benefits of these targeted therapies at a population level...
December 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28149767/metastatic-lymphoepithelioma-like-carcinoma-of-the-lung-treated-with-nivolumab-a-case-report-and-focused-review-of-literature
#4
Chul Kim, Arun Rajan, Pedro A DeBrito, Giuseppe Giaccone
In recent years, significant advances have been made in cancer immunotherapy. Here, we present the first report of a patient with lymphoepithelioma-like carcinoma (LELC) of the lung, an Epstein-Barr virus (EBV)-associated lung cancer, who was treated with nivolumab, a fully human IgG4 anti-PD-1 monoclonal antibody. We also carry out a focused review to identify and examine studies of LELC of the lung in the literature. This case report highlights the need to further assess the role of immune checkpoint inhibitors in LELC of the lung...
December 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28149766/unexpected-long-survival-of-brain-oligometastatic-non-small-cell-lung-cancer-nsclc-treated-with-multimodal-treatment-a-single-center-experience-and-review-of-the-literature
#5
Concetta Elisa Onesti, Daniela Iacono, Silvia Angelini, Salvatore Lauro, Marco Mazzotta, Mario Alberto Occhipinti, Raffaele Giusti, Paolo Marchetti
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death worldwide. Fifty percent of the cases are metastatic at diagnosis and about 20% develop brain metastasis. The brain involvement represents a negative prognostic factor. However, some patients could benefit from locoregional treatments of metastatic foci and experience an unexpected long survival or healing. In the previous years some classifications were proposed to identify patients' prognostic category, according to stage of the primary tumor, the timing of metastases occurrence (synchronous or metachronous) and the number of metastatic sites...
December 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28149765/a-rare-case-of-palatin-tonsillar-metastasis-from-small-cell-lung-cancer
#6
Chiara D'Antonio, Alberto Lombardini, Concetta Elisa Onesti, Rosa Falcone, Adriana Romiti, Marianna Lombardi, Salvatore Lauro, Paolo Marchetti
Tonsillar metastases are absolutely rare. Small cell lung cancer (SCLC) is known to be the most frequent histological type of tonsillar metastases, however the way of tumor cells spreading to tonsil remains controversial. We described a case report of 76-year-old man with SCLC and tonsillar metastases, to highlight the importance of oral cavity evaluation as a part of a clinical exam and to show the rare tumor cells spreading.
December 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28149764/third-generation-epidermal-growth-factor-receptor-tyrosine-kinase-inhibitors-in-t790m-positive-non-small-cell-lung-cancer-review-on-emerged-mechanisms-of-resistance
#7
REVIEW
Roberta Minari, Paola Bordi, Marcello Tiseo
Osimertinib, third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI), has been approved in the US and EU for the treatment of EGFR mutant T790M-positive non-small cell lung cancer (NSCLC) patients resistant to first- or second-generation EGFR-TKIs, such as gefitinib, erlotinib and afatinib. Although exciting survival data and response rates have been registered in patients treated with this and other third-generation EGFR-TKIs, unfortunately acquired resistance still occurs after approximately 10 months...
December 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28149763/statistical-control-process-to-compare-and-rank-treatment-plans-in-radiation-oncology-impact-of-heterogeneity-correction-on-treatment-planning-in-lung-cancer
#8
Abdulhamid Chaikh, Jacques Balosso
BACKGROUND: This study proposes a statistical process to compare different treatment plans issued from different irradiation techniques or different treatment phases. This approach aims to provide arguments for discussion about the impact on clinical results of any condition able to significantly alter dosimetric or ballistic related data. METHODS: The principles of the statistical investigation are presented in the framework of a clinical example based on 40 fields of radiotherapy for lung cancers...
December 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28149762/statistic-and-dosimetric-criteria-to-assess-the-shift-of-the-prescribed-dose-for-lung-radiotherapy-plans-when-integrating-point-kernel-models-in-medical-physics-are-we-ready
#9
Abdulhamid Chaikh, Jacques Balosso
BACKGROUND: To apply the statistical bootstrap analysis and dosimetric criteria's to assess the change of prescribed dose (PD) for lung cancer to maintain the same clinical results when using new generations of dose calculation algorithms. METHODS: Nine lung cancer cases were studied. For each patient, three treatment plans were generated using exactly the same beams arrangements. In plan 1, the dose was calculated using pencil beam convolution (PBC) algorithm turning on heterogeneity correction with modified batho (PBC-MB)...
December 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28149761/impact-of-dose-calculation-models-on-radiotherapy-outcomes-and-quality-adjusted-life-years-for-lung-cancer-treatment-do-we-need-to-measure-radiotherapy-outcomes-to-tune-the-radiobiological-parameters-of-a-normal-tissue-complication-probability-model
#10
Abdulhamid Chaikh, Nicolas Docquière, Pierre-Yves Bondiau, Jacques Balosso
BACKGROUND: The equivalent uniform dose (EUD) radiobiological model can be applied for lung cancer treatment plans to estimate the tumor control probability (TCP) and the normal tissue complication probability (NTCP) using different dose calculation models. Then, based on the different calculated doses, the quality adjusted life years (QALY) score can be assessed versus the uncomplicated tumor control probability (UTCP) concept in order to predict the overall outcome of the different treatment plans...
December 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28149760/comparison-of-methods-for-circulating-cell-free-dna-isolation-using-blood-from-cancer-patients-impact-on-biomarker-testing
#11
Clara Pérez-Barrios, Irene Nieto-Alcolado, María Torrente, Carolina Jiménez-Sánchez, Virginia Calvo, Lourdes Gutierrez-Sanz, Magda Palka, Encarnación Donoso-Navarro, Mariano Provencio, Atocha Romero
BACKGROUND: The implementation of liquid biopsy for biomarker testing and response to treatment monitoring in cancer patients would presumable increase laboratory throughput, requiring the development of automated methods for circulating free DNA (cfDNA) isolation. METHODS: The present study compares the MagNA Pure Compact (MPC) Nucleic Acid Isolation Kit I and Maxwell(®) RSC (MR) ccfDNA Plasma Kit and the later with QIAamp Circulating Nucleid Acid (QCNA) Kit using 57 plasma samples from cancer patients...
December 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28149759/ascend-2-a-canary-in-a-coal-mine-for-descending-to-second-line-treatment-for-alk-rearranged-non-small-cell-lung-cancer
#12
EDITORIAL
Viola W Zhu, Sai-Hong Ignatius Ou
No abstract text is available yet for this article.
December 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28149758/defining-the-endpoints-how-to-measure-the-efficacy-of-drugs-that-are-active-against-central-nervous-system-metastases
#13
REVIEW
Alessandra Fabi, Antonello Vidiri
Brain metastases (BMs) are the most common cause of malignant central nervous system (CNS) tumors in adults. In the recent past, patients with BMs were excluded from clinical trials, but now, with the advent of new biological and immunological drugs, their inclusion is more common. In the last era response and progression criteria used across clinical trials have defined the importance to consider not only measurement changes of brain lesions but also the modification of parameters related to the metastases such as metabolism of tissue and its pathological features...
December 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28149757/are-immune-checkpoint-blockade-monoclonal-antibodies-active-against-cns-metastases-from-nsclc-current-evidence-and-future-perspectives
#14
REVIEW
Grainne M O'Kane, Natasha B Leighl
Brain metastases occur in approximately half of patients with non-small cell lung cancer (NSCLC) and are associated with a poor prognosis and an inferior quality of life. Historically systemic therapy has had a limited role in CNS disease with a reliance placed on local treatments. The emergence of targeted therapies and immune checkpoint inhibitors (ICIs) in recent years has dramatically changed the treatment landscape of NSCLC. Programmed cell death-1 (PD-1) inhibitors have demonstrated efficacy in three randomized trials and now represent standard second line therapy after platinum failure...
December 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28149756/anti-angiogenetic-therapies-for-central-nervous-system-metastases-from-non-small-cell-lung-cancer
#15
REVIEW
Consuelo Buttigliero, Valentina Bertaglia, Silvia Novello
Central nervous system (CNS) metastases are common in patients with advanced non-small cell lung cancer (NSCLC), occurring in 24% to 44% of patients in the course of their disease and confer significant morbidity and mortality. Systemic therapies have been deemed ineffective in brain metastases (BM) under the hypothesis that the blood-brain barrier (BBB) limits their delivery to the brain. Angiogenesis, which is mainly mediated by vascular endothelial growth factor (VEGF) pathway, is crucial for tumor survival, growth and invasion both in primary and metastatic brain lesions...
December 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28149755/state-of-the-art-of-chemotherapy-for-the-treatment-of-central-nervous-system-metastases-from-non-small-cell-lung-cancer
#16
REVIEW
Alessandro Inno, Vincenzo Di Noia, Ettore D'Argento, Alessandra Modena, Stefania Gori
Chemotherapy is the mainstay of treatment of advanced non-small cell lung cancer (NSCLC) without molecular drivers. Despite a low penetration of central nervous system (CNS), chemotherapy drugs demonstrated encouraging activity against CNS metastases from NSCLC. Based on the available data, chemotherapy should be considered as an important part of the multidisciplinary treatment of CNS metastases. Particularly, platinum-based regimens represent the most active combinations and pemetrexed is associated with a meaningful clinical benefit for patients with non-squamous histology...
December 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28149754/non-small-cell-lung-cancer-nsclc-and-central-nervous-system-cns-metastases-role-of-tyrosine-kinase-inhibitors-tkis-and-evidence-in-favor-or-against-their-use-with-concurrent-cranial-radiotherapy
#17
REVIEW
Panagiota Economopoulou, Giannis Mountzios
Central nervous system (CNS) metastases, including brain metastases (BM) and leptomeningeal metastases (LM) represent a frequent complication of non-small cell lung cancer (NSCLC). Patients with BM comprise a heterogeneous group, with a median survival that ranges from 3 to 14 months. However, in the majority of patients, the occurrence of CNS metastases is usually accompanied by severe morbidity and substantial deterioration in quality of life. Local therapies, such as whole brain radiotherapy (WBRT), stereotactic radiosurgery (SRS) or surgical resection, either alone or as part of a multimodality treatment are available treatment strategies for BM and the choice of therapy varies depending on patient group and prognosis...
December 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28149753/achievements-and-future-developments-of-alk-tkis-in-the-management-of-cns-metastases-from-alk-positive-nsclc
#18
REVIEW
Lorenza Landi, Federico Cappuzzo
Non-small cell lung cancer (NSCLC) represents the paradigm of personalized treatment of human cancer. Several oncogenic druggable alterations have been so far identified, with anaplastic lymphoma kinase (ALK) gene rearrangements being one of the newest and most appealing. Presence of ALK fusions is associated with some particular clinical and pathological features, including a preferential seeding into the central nervous system (CNS). In addition, ALK rearrangements are recognized as the strongest predictor for benefit of anti-ALK therapy...
December 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28149752/epidermal-growth-factor-receptor-tyrosine-kinase-inhibitors-for-the-treatment-of-central-nervous-system-metastases-from-non-small-cell-lung-cancer-the-present-and-the-future
#19
REVIEW
Claudia Proto, Martina Imbimbo, Rosaria Gallucci, Angela Brissa, Diego Signorelli, Milena Vitali, Marianna Macerelli, Giulia Corrao, Monica Ganzinelli, Francesca Gabriella Greco, Marina Chiara Garassino, Giuseppe Lo Russo
Lung cancer is one of the major causes of cancer related mortality worldwide. Brain metastases (BM) complicate clinical evolution of non-small cell lung cancer (NSCLC) in approximately 25-40% of cases, adversely influencing quality of life (QoL) and overall survival (OS). Systemic therapy remains the standard strategy for metastatic disease. Nevertheless, the blood-brain barrier (BBB) makes central nervous system (CNS) a sanctuary site. To date, the combination of chemotherapy with whole brain radiation therapy (WBRT), surgery and/or stereotactic radiosurgery (SRS) represents the most used treatment for patients (pts) with intracranial involvement...
December 2016: Translational Lung Cancer Research
https://www.readbyqxmd.com/read/28149751/preface-on-emerging-treatment-options-for-brain-metastases-from-non-small-cell-lung-cancer
#20
Giulio Metro, Rita Chiari
No abstract text is available yet for this article.
December 2016: Translational Lung Cancer Research
journal
journal
49936
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"